Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin

Pharmaceutical Research

Volumn 22, Issue 11, 2005, Pages 1954-1963

  Li, Jing ^a,c   Zhou, Shufeng ^a   Huynh, Hung ^b   Duan, Wei ^a   Chan, Eli ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

COL 3; Doxorubicin; Gastrointestinal toxicity; Matrix metalloproteinase inhibitor; Pharmacokinetic interaction

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; DOXORUBICIN; MATRIX METALLOPROTEINASE INHIBITOR;

ACUTE DIARRHEA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT; CANNULATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG URINE LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTESTINE INJURY; MALE; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACUTE DISEASE; ANIMALS; BLOOD PROTEINS; DIARRHEA; DOXORUBICIN; DRUG INTERACTIONS; GASTROINTESTINAL TRACT; MALE; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TETRACYCLINES;

EID: 27144533896     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-6096-4     Document Type: Article

References (34)

1. M. A. Rudek W. D. Figg V. Dyer W. Dahut M. L. Turner S. M. Steinberg D. J. Liewehr D. R. Kohler J. M. Pluda E. Reed 2001 Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer J. Clin. Oncol. 19 584 592
2. M. Cianfrocca T. P. Cooley J. Y. Lee M. A. Rudek D. T. Scadden L. Ratner J. M. Pluda W. D. Figg S. E. Krown B.J. Dezube 2002 Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study J. Clin. Oncol. 20 153 159
3. P. Maisi M. Kiili S. M. Raulo E. Pirila T. Sorsa 1999 MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid Ann. NY Acad. Sci. 878 675 677
4. H. M. Lee L. M. Golub J. Cao O. Teronen M. Laitinen T. Salo S. Zucker T. Sorsa 2001 CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer Curr. Med. Chem. 8 257 260
5. B. L. Lokeshwar M. G. Selzer B. Q. Zhu N. L. Block L.M. Golub 2002 Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model Int. J. Cancer 98 297 309
6. R. E. Seftor E. A. Seftor J. E. De De Larco D. E. Kleiner J. Leferson W. G. Stetler-Stevenson T. F. McNamara L. M. Golub M. J. Hendrix 1998 Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis Clin. Exp. Metastasis 16 217 225
7. M. Egeblad Z. Werb 2002 New functions for the matrix metalloproteinases in cancer progression Nat. Rev., Cancer 2 161 174
8. S. Zucker J. Cao W. T. Chen 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 6642 6650
9. R. Hoekstra F. A. Eskens J. Verweij 2001 Matrix metalloproteinase inhibitors: current developments and future perspectives Oncologist 6 415 427
10. L. M. Coussens B. Fingleton L. M. Matrisian 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2387 2392
11. W. G. Stetler-Stevenson 1997 Matrix metalloproteinase inhibitors B. A. Teicher Cancer Therapeutics: Experimental and Clinical Agents Humana Press Inc. Totowa, NJ 241 261
12. I. J. Fidler L. M. Ellis 2000 Chemotherapeutic drugs-More really is not better Nat. Med. 6 500 502
13. R. Giavazzi A. Garofalo C. Ferri V. Lucchini E. A. Bone S. Chiari P. D. Brown M. I. Nicoletti G. Taraboletti 1998 Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts Clin. Cancer Res. 4 985 992
14. D. R. Shalinsky J. Brekken H. Zou L. A. Bloom C. D. McDermott S. Zook N. M. Varki K. Appelt 1999 Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies Clin. Cancer Res. 5 1905 1917
15. D. R. Shalinsky J. Brekken H. Zou C. D. McDermott P. Forsyth D. Edwards S. Margosiak S. Bender G. Truitt A. Wood N. M. Varki K. Appelt 1999 Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials Ann. NY Acad. Sci. 878 236 270
16. M. Pavlaki S. Zucker 2003 Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev. 22 177 203
17. J. Y. Douillard C. Peschel F. Shepherd L. Paz-Ares A. Arnold M. Davis M. Tonato M. Smylie D. Tu M. Voi J. Humphrey J. Ottaway K. Young A. V. Vreckem L. Seymour 2004 Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer Lung Cancer 46 361 368
18. J. H. Doroshow 1996 Anthracyclines and anthracenediones D. L. Longo Cancer Chemotherapy and Biotherapy Lippincott-Raven Publishers Philadelphia 409 434
19. J. Li H. Huynh E. Chan 2002 Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration Pharm. Res. 19 1655 1662
20. O. C. Trifan W. F. Durham V. S. Salazar J. Horton B. D. Levine B. S. Zweifel T. W. Davis J. L. Masferrer 2002 Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 Cancer Res. 62 5778 5784
21. A. Kurita S. Kado N. Kaneda M. Onoue S. Hashimoto T. T. Yokokura 2000 Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats Cancer Chemother. Pharmacol. 46 211 220
22. I. Maric L. Poljak S. Zoricic D. Bobinac D. Bosukonda K. T. Sampath S. Vukicevic 2003 Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats J. Cell. Physiol. 196 258 264
23. J. Li S.-F. Zhou H. Huynh E. Chan 2005 Significant intestinal excretion, one source of the variability in pharmacokinetics of COL-3, a chemically modified tetracycline Pharm. Res. 22 397 404
24. J. Li H. Huynh E. Chan 2004 Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples J. Chromatogr., B Analyt. Technol. Biomed. Life Sci. 799 311 321
25. R. H. Stephens C. A. O'Neill A. Warhurst G. L. Carlson M. Rowland G. Warhurst 2001 Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J. Pharmacol. Exp. Ther. 296 584 591
26. F. Formelli R. Carsana C. Pollini 1987 Pharmacokinetics of 4′-deoxy-4′-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin Cancer Res. 47 5401 5406
27. J. Cummings C. S. McArdle 1986 Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug Br. J. Cancer 53 835 858
28. H. S. Schwartz 1973 A fluorometric assay for daunomycin and adriamycin in animal tissues Biochem. Med. 7 396 404
29. W. H. Kruskal W. A. Wallis 1952 Use of ranks in one-criterion variance analysis J. Am. Stat. Assoc. 47 583 621
30. M. Rowland T. Tozer 1995 Absorption M. Rowland T. Tozer Clinical Pharmacokinetics: Concepts and Applications Williams & Wilkins London 119 136
31. K. Behnia M. Boroujerdi 1999 Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats J. Pharm. Pharmacol. 51 1275 1282
32. P. A. Speth Q. G. van van Hoesel C. Haanen 1988 Clinical pharmacokinetics of doxorubicin Clin. Pharmacokinet. 15 15 31
33. S. S. Legha G. N. Hortobagyi B. S. Benjamin 1987 Anthracyclines J. J. Lokich Cancer Chemotherapy by Infusion Precept Press Chicago 100 113
34. J. Chen M. Bookbinder M. E. Ryan L. M. Golub R. Ashley N. S. Ramamurthy 2001 Biodistribution of radiolabeled [(3)H] CMT-3 in rats Curr. Med. Chem. 8 253 256